Phase 2 Pulmonary Hypertension Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older.
• People who are able to give informed consent to participate.
• People who are able to follow all study procedures as required.
• People who have a history of right-sided heart weakness or right heart failure caused by one of the following: a type of high blood pressure in the lungs called pulmonary arterial hypertension (Group 1); high blood pressure in the lungs related to left heart disease, where the left side of the heart is still pumping normally but a previous heart catheter test showed specific pressure and resistance readings (Group 2); lung disease-related high blood pressure in the lungs (Group 3); or a type caused by blood clots in the lungs that persists after surgery or cannot be operated on (Group 4).
• People who currently have symptoms rated as Class II, III, or IV under a standard heart symptom scale (meaning symptoms range from mild limitation during activity to discomfort even at rest).
• People who have had a blood test and heart ultrasound within the last 3 months showing right-sided heart weakness, meeting specific measurements for a blood marker (NT-proBNP) and heart ultrasound findings including reduced heart muscle movement and an enlarged right side of the heart (confirm specific thresholds with trial site).
• People who have been taking water tablets (loop diuretics) or a related heart medication (mineralocorticoid receptor antagonists) for at least 4 weeks.
• People who have access to a smartphone or tablet running iOS or Android.

Who may not be able to join:

• People whose kidneys are not working well enough, based on a standard kidney function score below a certain level (confirm specific threshold with trial site).
• People whose left side of the heart is not pumping strongly enough (pumping less than 50% of blood with each beat).
• People whose right side of the heart is a normal size and working normally.
• People with severe disease of the aortic or mitral heart valves.
• People with moderate or severe liver disease (classified as Child-Pugh Class B or C).
• People whose fluid or water tablet treatment is not considered stable at the time of screening.
• People who are pregnant or breastfeeding.
• People who are unable to give consent or attend follow-up visits.
• People who are already on a waiting list for a lung, heart, or combined heart-lung transplant.
• People who had a heart attack or acute heart event within 90 days before screening.
• People who are already enrolled in another interventional clinical trial.
• People who have a planned heart or chest surgery scheduled within the next 6 months.
• People with a known allergy or sensitivity to the medications empagliflozin or ranolazine.
• People currently taking certain medications that interact with the study drugs, including specific antifungal, antibiotic, antiviral, heart rhythm, and seizure medications, as well as St. John's wort or grapefruit juice (confirm the full medication list with the trial site).
• People with a specific inherited heart rhythm condition (congenital long QT syndrome) or an abnormal heart rhythm reading above a certain level on an ECG (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.